Head to head comparison teriparatide products daily versus weekly for osteoporosis patients.

Head to head comparison teriparatide products daily versus weekly for osteoporosis patients. - The Efficacy of teriparatide products daily vs weekly.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000024503

Enrollment

Registered

2016-11-01

Start date

2013-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Interventions

Teriparatide 20 microgram sc daily (104weeks) -&gt

Denosmab 60mg Q26weeks (52weeks) Teriparatide acetate 56.5 microgram sc weekly (72weeks) -&gt

Denosmab 60mg Q26weeks (40weeks)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients of post menopausal osteoporosis, male osteoporosis and glucocorticoid induced osteoporosis.

Exclusion criteria

Exclusion criteria: The patient who has poor control of the underlying disease in the glucocorticoid osteoporosis

Design outcomes

Primary

Measure	Time frame
The new bone fracture incidence until 18 months after treatment intervention.	—

Secondary

Measure	Time frame
Change of the serologic marker about bone metabolism and the bone density 1, 6, 12, 18 and 30 months later. The new bone fracture incidence until 30 months after treatment intervention. serologic marker: TRACP-5b, total P1NP, 1,25(OH)2VitD3, Ca, IP	—

Countries

Japan

Contacts

Public ContactTakafumi Hagiwara

Takarazuka city hospital Department of rheumatology

college@katzenauge.sakura.ne.jp0797-87-1161

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026